Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2019 Sep 3;84(5):993–1001. doi: 10.1007/s00280-019-03939-7

Table 2:

Final Population PK Model Parameters and Bootstrap Estimate

Final Parameter Standard Error Bootstrap Estimates* (Median and 95% CI)
Θ1 (VI) 3.66 0.064 3.67 (3.55 – 3.78)
Θ2 (CL) 0.214 0.00816 0.216 (0.20 – 0.23)
Θ3 (V2) 3.13 0.088 3.14 (2.97 – 3.31)
Θ4 (Q) 0.624 0.0456 0.62 (0.55 – 0.72)
Θ5 (Albumin CL) −0.84 0.17 −0.86 (−1.14 - −0.53)
Θ6 (Weight Vss) 0.65 0.056 0.64 (0.54 – 0.75)
Θ7 (Albumin Vss) −0.35 0.11 −0.32 (−0.53 - −0.15)
Θ8 (HV on Vss) 0.83 0.025 0.82 (0.78 – 0.87)
Θ9 (SMM on Vss) 0.77 0.025 0.77 (0.72 – 0.83)
Θ10 (HV on CL) 0.77 0.041 0.77 (0.70 – 0.83)
Θ11 (ALT CL) −0.096 0.041 −0.097 (−0.18 - −0.013)
Θ12 (SCR Vss) 0.16 0.051 0.15 (0.062 – 0.25)
Θ13 (CD on CL) 1.24 0.081 1.24 (1.11 – 1.45)
Variability (η)
Between-subject (CL) 20.0% 0.11% 19.9% (17.8% - 22.1%)
Between-subject (Vss) 42.0% 1.71% 41.0% (37.8% - 44.5%)
Error (ε)
Proportional 22.4% 0.79% 22.2% (20.8% - 23.8%)
Additive 0.0217 0.0028 0.022 (0.0005 – 0.056)
*

Bootstrap successfully converged 98.9%

Abbreviations: ALB=albumin, ALT=alanine aminotransferase, CD=Castleman’s disease, CL=clearance, HV=healthy volunteers, SCR= serum creatinine, SMM=smoldering multiple myeloma, V1=central volume of distribution, V2=peripheral volume of distribution, Vss=covariate assessed on both V1 and V2

CL (L/day) = 0.214 x (ALB/4.1)−0.84 x (0.77 if HV) x (ALT/17)−0.096 x (1.24 if CD)

Vss (L) = (3.66 + 3.13) x (WT/73)0.65 x (ALB/4.1)−0.35 x (0.83 if HV) x (0.77 if SMM) x (SCR/0.894)0.16